March 2026 in “Molecular and Cellular Biomedical Sciences” This study found that exosomes derived from hypoxia-conditioned mesenchymal stem cells modulated inflammatory biomarkers by decreasing CXCL12 and increasing IL-10 expression in a DHT-induced androgenic alopecia mouse model, indicating potential for treating hair loss through immunoregulation.
April 2026 in “Journal of Biomedicine and Translational Research” In this study, exosomes from hypoxia-conditioned mesenchymal stem cells significantly improved SOCS3 and STAT3 expression in a mouse model of androgenetic alopecia, suggesting they may offer a more effective therapeutic approach than minoxidil by restoring follicular homeostasis.
March 2026 in “Medeniyet Medical Journal” This study found that hypoxia-conditioned mesenchymal stem cell exosomes increased GM-CSF and decreased IL-1 expression in a dose-dependent manner in a murine model, suggesting potential for treating androgenetic alopecia.
16 citations
,
January 2024 in “World Journal of Stem Cells” This review highlights the need for optimizing mesenchymal stromal/stem cell therapy through tailored in vitro strategies to unlock their full potential for treating specific diseases.
April 2026 in “Biosaintifika Journal of Biology & Biology Education” This study found that in a fluconazole-induced alopecia-like rat model, a 14-day treatment with hypoxia-induced mesenchymal stem cell exosomes significantly increased TGF-β and PDGF levels, which may improve hair growth and suggests a potential therapeutic strategy for alopecia and other inflammation-related skin disorders.